Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2009 - 2025)

Ironwood Pharmaceuticals has disclosed Gains from Sales and Divestitures across 16 years of filings, most recently posting $194488.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $194488.0, down 75.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $194488.0 (down 75.77% YoY), and the FY2025 annual result was $194488.0, down 75.77% from the prior year.
• Gains from Sales and Divestitures came in at $194488.0 for Q4 2025 at Ironwood Pharmaceuticals, down from $802800.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.7 million in Q4 2021 to a low of $71588.0 in Q4 2023.
• The 5-year median for Gains from Sales and Divestitures is $802800.0 (2024), against an average of $818838.8.
• Across the five-year window, Gains from Sales and Divestitures plunged 94.61% in 2023 and jumped 1021.42% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Gains from Sales and Divestitures stood at $1.7 million in 2021, then declined by 21.8% to $1.3 million in 2022, then slumped by 94.61% to $71588.0 in 2023, then surged by 1021.42% to $802800.0 in 2024, then sank by 75.77% to $194488.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $194488.0 (Q4 2025), $802800.0 (Q4 2024), and $71588.0 (Q4 2023), per Business Quant data.